Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

For the breakthrough perioperative head and neck cancer indication, Keytruda is only allowed in patients with PD-L1-positive tumors.

Purpose The etiology, diagnosis, staging, and management of malignant pleural mesothelioma (MPM) are reviewed, with an emphasis on clinical trials of newer approaches to first-line, second-line ...

May 31 (Reuters) - Gilead Sciences' (GILD.O) Trodelvy in combination with Merck's (MRK.N) blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35 ...

The drug is currently being evaluated in a Phase III trial for malignant pleural mesothelioma (NCT06097728). In September 2024, the FDA approved MSD’s Keytruda in combination with chemotherapy as a ...

Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) ...

"This approval marks the first combination treatment of KEYTRUDA ® and chemotherapy in Canada for patients with malignant pleural mesothelioma," says Dr. Quincy Chu, Medical Oncologist at the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with ...

The FDA has approved only two new therapies since 2000, both improving survival by only a few months. Researchers at Memorial Sloan Kettering Cancer Center have been exploring the use of chimeric ...

Malignant Pleural Mesothelioma (MPM): KEYTRUDA as a first-line treatment may be combined with chemotherapy medicines to treat MPM, a cancer that affects the lining of the lungs and chest wall.